The biotechnology company specified that "to its knowledge, there is no intention of a takeover of the company, nor any process or evaluation to that effect." Furthermore, Nanobiotix explained that it has identified factual inaccuracies in the media report that are inconsistent with the company's latest public disclosures. This likely refers to a report by La Lettre, which earlier suggested interest from Johnson & Johnson in acquiring the French firm.

The two companies have been linked since 2023 by a global licensing, co-development, and commercialization agreement. This agreement was further amended in March 2025 to allow the French company to reduce its financing requirements.

Specifically, the agreement amended a year ago provides for the removal of Nanobiotix's commitment to fund the Nanoray-312 study in exchange for waiving certain potential future milestone payments, while maintaining Nanobiotix's ability to generate revenue through significant potential milestone payments. The total value of the global licensing contract was adjusted from approximately 2.7 to 2.6 billion dollars.

Nanobiotix's lead product is NBTXR3 (or JNJ-1900), a potentially first-in-class oncology treatment administered via intratumoral injection and activated by radiotherapy. It is being evaluated across multiple solid tumors, either as a monotherapy or in combination with other agents, notably in a randomized Phase 3 study for locally advanced head and neck cancers.